Amprion

Amprion is the global leader advancing diagnosis of neurodegenerative disorders like Alzheimer's and Parkinson's disease through seed amplification testing.

[Amprion @AmprionDx]

Don't miss the Life Sciences Success Podcast: Dr. Russ Lebovitz (Amprion Cofounder and CEO): Revolutionizing Brain Health with Early Detection tomorrow (Sept. 25) LIVE at 2 pm Pacific/4 pm Central. Register here: https://t.co/1zIhoo9GfD

[Amprion @AmprionDx]

That’s a wrap on the 2025 International Lewy Body Dementia Conference! We’re grateful for the opportunity to connect with leading researchers, clinicians, and partners working to advance LBD diagnosis and care. #ILBDC2025

[Amprion @AmprionDx]

"It’s #WorldLewyBodyDementiaDay—a day to raise awareness and support the LBD community. Awareness is critical, as early and accurate diagnosis can transform lives.

At Amprion, we’re proud to offer tools to aid in diagnosing LBD and related neurodegenerative diseases.

[Amprion @AmprionDx]

🚀 "2025 will be monumental for neurodegenerative diseases! Expect silos between Alzheimer's, Parkinson's, ALS & more to merge." - Russ Lebovitz, Amprion; read more Predictions for Diagnostics World in 2025 hashtag#NeuroScience hashtag#Biomarkers
https://t.co/8dDsuAhSDo

[Amprion @AmprionDx]

Clinical implications of new research study in The Lancet Neurology are transformative for MSA diagnosis: Amprion's synSAA distinguishes multiple system atrophy (MSA) from Parkinson’s, with 100% accuracy. Learn more. #MSAResearch #NeuroScienceInnovation
https://t.co/KiQ2F85h11

[Amprion @AmprionDx]

Join us in celebrating! Amprion's SAAmplify™-ɑSYN assay wins 2024 Clinical Diagnostics Solution of the Year! 🌟Transforming neurodegenerative diagnoses like Parkinson’s & Alzheimer’s, it’s an innovation whose time has come! #BiotechBreakthrough2024 https://t.co/O4sqA4UcPJ

[Amprion @AmprionDx]

Cheers to Amprion co-founder Dr. Claudio Soto, awarded the 2024 Robert A. Pritzker Prize by @MichaelJFoxOrg! 🎉 His innovations, like αSyn-SAA, bring hope to millions by advancing Parkinson’s diagnostics & therapies. 💡#ParkinsonsProgress https://t.co/mc3tVuH0P4

[Amprion @AmprionDx]

Good news today in the Washington Post: "Parkinson’s is often misdiagnosed. New tests may change that." Our SAAmplify-ɑSYN Test is available now in the US to aid in diagnosis of #Parkinsons, DLB, & Alzheimer’s disease with Lewy body copathology. https://t.co/nXJwX8sGj6

[Amprion @AmprionDx]

Today is World Alzheimer’s Day–a great chance to learn more and get involved. Amprion is committed to keep exploring, innovating, and collaborating to facilitate the end of Alzheimer’s for today’s and tomorrow’s patients. #ENDALZ #EarlyDetection #Alzheimers

[Amprion @AmprionDx]

@youralsnetwork Amprion is honored to help advance medicine for sporadic ALS. #cureALStogether

[ALS Network @youralsnetwork]

A $100K grant has been awarded to @AmprionDx by @youralsnetwork through its global research program. Amprion seeks to understand the cause of sporadic ALS & actively assist in the development of potential therapies by supporting clinical & lab research. https://t.co/IT0IlfhcMh

[Amprion @AmprionDx]

FDA Issues Letter of Support for α-Synuclein Seed Amplification Assay – The Core Technology Used in Amprion’s First Commercial Test #Parkinsons

https://t.co/epLP1dUDTN